Access to Medicines

Access to Medicines

Scoping a Compulsory Licensing Strategy for Countries Excluded from Gilead’s L... 

Access to Medicines

Guia do ativista dia mundial de luta contra aids 2024: Acesso global ao lenacapa... 

Access to Medicines

World AIDS Day Activist Toolkit: Global Access to Generic Lenacapavir Now! 

Access to Medicines

Expanding Frontiers for Compulsory Licensing 

Access to Medicines

Supporting Equitable Access to Medicines in the WHO Pandemic Agreement 

Access to Medicines

Letter to Procurement Agents: Say No to Secrecy in Medical Product Agreements 

Access to Medicines

Special 301 Review Comment 

Access to Medicines

Comment Re: Implications of Access and Benefit Sharing Commitments/Regimes and O... 

Access to Medicines

The Big Pharma Bullies: Secrecy for Vaccine Supplies in a Pandemic 

Access to Medicines

Hearing Testimony: COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TR... 

Access to Medicines

COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexi... 

Access to Medicines

TRIPS-Compliant Alternatives for Overcoming Intellectual Property Barriers to CO...  

Access to Medicines

Letter to ViiV re CAB-LA for PrEP  

Access to Medicines

BMJ Global Health: A pandemic treaty for equitable global access to medical coun...  

Access to Medicines

Letter to Pres. Biden on COVID19 Global Summit May 2022 

Access to Medicines

Amicus Brief on Human Rights Principles and TRIPS-Compliant Interpretation to th... 

Access to Medicines

Policy Brief: Community-Based COVID-19 Test-and-Treat (April 2022) 

Access to Medicines

Community-Based Test-and-Treat 

Access to Medicines

To Save Lives, a COVID Intellectual Property Waiver Must Cover Medicines and Oth... 

Access to Medicines

Request of Least Developed Countries for Extension of Transition Period